Pancoast tumor classification: Difference between revisions
Mazia Fatima (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) |
||
Line 13: | Line 13: | ||
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''M''' | | style="background:#4479BA; color: #FFFFFF;" align="center" + |'''M''' | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + | | | style="background:#DCDCDC;" align="center" + |IIB | ||
| style="background:#F5F5F5;" + | | | style="background:#F5F5F5;" + |T3 | ||
| style="background:#F5F5F5;" + |N0 | | style="background:#F5F5F5;" + |N0 | ||
| style="background:#F5F5F5;" + |M0 | | style="background:#F5F5F5;" + |M0 | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + | | | style="background:#DCDCDC;" align="center" + |IIIA | ||
| style="background:#F5F5F5;" + |T3 | | style="background:#F5F5F5;" + |T3 | ||
| style="background:#F5F5F5;" + | | | style="background:#F5F5F5;" + |N1-2 | ||
| style="background:#F5F5F5;" + |M0 | | style="background:#F5F5F5;" + |M0 | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + | | | style="background:#DCDCDC;" align="center" + |IIIB | ||
| style="background:#F5F5F5;" + |T4 | | style="background:#F5F5F5;" + |T4 | ||
| style="background:#F5F5F5;" + |Any N | | style="background:#F5F5F5;" + |Any N | ||
| style="background:#F5F5F5;" + |M0 | | style="background:#F5F5F5;" + |M0 | ||
|- | |||
|IIIB | |||
|Any T | |||
|N3 | |||
|M0 | |||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |IV | | style="background:#DCDCDC;" align="center" + |IV | ||
Line 44: | Line 39: | ||
|} | |} | ||
{| class="wikitable" align="center" | {| class="wikitable" align="center" | ||
| colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + | | | colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |TNM-8th Edition | ||
|- | |- | ||
! rowspan="4" style="background:#DCDCDC;" align="center" + | T | ! rowspan="4" style="background:#DCDCDC;" align="center" + | T | ||
| style="background:#DCDCDC;" align="center" + | T1 | | style="background:#DCDCDC;" align="center" + | T1 | ||
| style="background:#F5F5F5;" + | | | style="background:#F5F5F5;" + |Tumor size ≤3cm in greatest dimension | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |T2 | | style="background:#DCDCDC;" align="center" + |T2 | ||
| style="background:#F5F5F5;" + |> | | style="background:#F5F5F5;" + | | ||
* Tumor size >3cm to ≤5cm | |||
* Tumor of any size that | |||
** invades the visceral pleura | |||
** involves main bronchus, irrespective of distance to the carina | |||
** shows an atelectasis or obstructive pneumonitis that extends to the hilum | |||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |T3 | | style="background:#DCDCDC;" align="center" + |T3 | ||
| style="background:#F5F5F5;" + | | | style="background:#F5F5F5;" + | | ||
* Tumor size >5cm to 7cm | |||
* Pancoast that involves thoracic nerve roots T1 and T2 only. | |||
* Tumor of any size that | |||
** invades the chest wall | |||
** invades the pericardium | |||
** invades the phrenic nerve | |||
** involves main bronchus, irrespective of distance to the carina | |||
** shows one or more satellite nodules in the same lung lobe | |||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |T4 | | style="background:#DCDCDC;" align="center" + |T4 | ||
| style="background:#F5F5F5;" + |Involvement of the | | style="background:#F5F5F5;" + | | ||
* Tumor size >7cm | |||
* Involvement of C8 or higher nerve roots, brachial plexus, subclavian vessels or spine | |||
* Tumor of any size that | |||
** invades mediastinal fat or mediastinal structures | |||
** invades the diaphragm | |||
** involves the carina | |||
** shows one or more satellite nodules in another lobe on the ipsilateral side | |||
|- | |- | ||
! rowspan=" | ! rowspan="4" style="background:#DCDCDC;" align="center" + | N | ||
| style="background:#DCDCDC;" align="center" + |N0 | | style="background:#DCDCDC;" align="center" + |N0 | ||
| style="background:#F5F5F5;" + |No regional [[lymph node]] [[metastasis]] | | style="background:#F5F5F5;" + |No regional [[lymph node]] [[metastasis]] | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |N1 | | style="background:#DCDCDC;" align="center" + |N1 | ||
| style="background:#F5F5F5;" + | | | style="background:#F5F5F5;" + |Nodes are ipsilateral nodes within the lung up to hilar nodes. | ||
|- | |||
!N2 | |||
!Nodes represent ipsilateral mediastinal or subcarinal lymphadenopathy. | |||
|- | |||
!N3 | |||
!'''Nodes represent contralateral mediastinal or contralateral hilar lymphadenopathy or any scalene or supraclavicular nodes.''' | |||
|- | |- | ||
! rowspan="2" style="background:#DCDCDC;" align="center" + | M | ! rowspan="2" style="background:#DCDCDC;" align="center" + | M |
Revision as of 00:06, 20 February 2018
Pancoast tumor Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Pancoast tumor classification On the Web |
American Roentgen Ray Society Images of Pancoast tumor classification |
Risk calculators and risk factors for Pancoast tumor classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Classification
- The staging of pancoast tumor is based on the TNM system.
- Pancoast tumors staging starts at T3 always, as there is invasion of chest wall. Invasion of vertebral body or the subclavian vessels is regarded as T4.
Stage | T | N | M |
IIB | T3 | N0 | M0 |
IIIA | T3 | N1-2 | M0 |
IIIB | T4 | Any N | M0 |
IIIB | Any T | N3 | M0 |
IV | Any T | Any N | M1 |
TNM-8th Edition | |||
T | T1 | Tumor size ≤3cm in greatest dimension | |
---|---|---|---|
T2 |
| ||
T3 |
| ||
T4 |
| ||
N | N0 | No regional lymph node metastasis | |
N1 | Nodes are ipsilateral nodes within the lung up to hilar nodes. | ||
N2 | Nodes represent ipsilateral mediastinal or subcarinal lymphadenopathy. | ||
N3 | Nodes represent contralateral mediastinal or contralateral hilar lymphadenopathy or any scalene or supraclavicular nodes. | ||
M | M0 | No distant metastasis | |
M1 | Distant metastasis |
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
- There is no established system for the classification of [disease name].
OR
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [Group1]
- [Group2]
- [Group3]
- [Group4]
OR
- [Disease name] may be classified into [large number > 6] subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
- [Disease name] may be classified into several subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
OR
- Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
- If the staging system involves specific and characteristic findings and features:
- According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
- The staging of [malignancy name] is based on the [staging system].
OR
- There is no established system for the staging of [malignancy name].